Clinical trial NCT05696691: Ketamine & Crisis Response Plan for Suicidal Ideation in the ED
Official title: A Randomized Pilot Trial of Intramuscular Ketamine and Crisis Response Planning for Suicide Prevention in the Emergency Department
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Suicide
Keywords: Ketamine
Crisis Response Plan
Suicidal Ideation
Emergency Department
Acute Suicidality
Intramuscular Ketamine
Emergency Room
Lead sponsor: The University of Texas Health Science Center at San Antonio
Sponsor class: OTHER
Collaborators: name: National Center for Advancing Translational Sciences (NCATS)
First posted: 2023-01-25
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: The goal of this randomized pilot trial is to assess the feasibility of administering a combination of 100mg intramuscular (IM) ketamine and Crisis Response Plan (a short psychosocial intervention) for patients with acute suicidality in the context of the Emergency Department setting. This study will assess a combination of a pharmacologic intervention and a psychosocial one. The pharmacologic intervention is a one-time dose of 100mg ketamine delivered intramuscularly (IM) while the patient is in the ED. The psychosocial intervention under study is a brief, patient-centered therapy which takes, on average, 30 minutes to administer. Both interventions will be administered only once. The main questions this study aims to answer are:

* Determine if 100mg of IM ketamine and Crisis Response Plan in combination results in greater short-term reductions in suicidal ideation in adult patients who report acutely elevated suicide risk during an ED visit.
* Examine potential weight-based dose response differences in the reductions in suicidal ideation to determine if future treatment protocols with IM ketamine may benefit from weight-based dosing.

Detailed description: This study is a phase II/III Clinical Pilot Trial. The study participants will be randomized to one of two groups: IM ketamine plus Crisis Response Planning (intervention group) or usual care (control group). Prior to treatment, we will obtain demographic and contact information for patients and for a friend/family member as a collateral reporter of symptom change and safety. As part of informed consent, participants will be warned about the potential for temporary effects of ketamine and provided an enrollment card to inform other care providers of their participation in a ketamine study. Participants will be weighed and complete a series of brief survey assessments. Clinical assessments such as history, physical examination, and routine laboratory testing will be collected as part of usual care. Ketamine and Crisis Response Planning will be administered, and study assessments will be repeated at 120 minutes posttreatment. To ensure the highest level of patient safety, we are proposing only to include patients who have already been cleared for a psychiatric hospitalization. This will also allow for close monitoring of symptom changes during the initial hours and days following treatment. Outcome measures will be collected at two hours, 3 days, and 1 month after the intervention. Research staff will collect assessments by telephone interview and/or visits. Consistent with established protocols, staff will be trained and supervised by STRONG STAR mental health professionals with expertise in evidence-based processes for assessing and responding to suicide risk. Trained and experienced therapists are available to meet with participants to develop a Crisis Response Plan at University Hospital.

Eligibility criteria: Inclusion Criteria:

* Adult men and women between the ages of 18 and 70 presenting to the Emergency Department with acute suicidal ideation.
* Patient cleared for admission to the University Hospital inpatient psychiatric unit.
* Decision to admit the patient to the inpatient unit or psychiatric stabilization unit made prior to consent to prevent study procedures from complicating or influencing the disposition and treatment as usual for suicidal patients reporting to the ED.
* Individuals presenting to the ED for other complaints but found to have suicidal ideation necessitating admission will also be eligible.
* Able to read and write English.

Exclusion Criteria:

* Serious mental illness with active and significant signs of psychosis, mania, hallucinations, paranoia, agitation, and drug-induced or other toxidromic symptoms.
* Acute intoxication with clinically significant symptoms (as defined by the attending clinician's assessment of patients' clinical sobriety).
* The patient is not capable of understanding the research procedures and providing informed consent for themselves.
* Lack of reliable means to be available for follow-up assessments (e.g, working mobile phone).
* Persistent resting blood pressure lower than 90/60 or higher than 180/110, or persistent resting heart rate lower than 45 beats/minute or higher than 120 beats/minute.
* Injuries requiring procedural sedation.
* Pregnancy or breast feeding.
* Known hypersensitivity to ketamine.
* Legal or illegal use of ketamine in the previous 90 days.
* End-stage or severe cardiovascular (e.g., ACS or decompensated heart failure), liver, or kidney disease.
* Patient is a prisoner.
* Patient is physically restrained or actively under custody of law enforcement. Once a patient is no longer under custody of law enforcement or physically restrained, the patient may be considered eligible and may consent to voluntary enrollment in the study.

Primary outcomes:
measure: Feasibility of study interventions
timeFrame: 30 days
Secondary outcomes:
measure: Change in Beck Scale for Suicidal Ideation (SSI) Score
timeFrame: Baseline to 30 days
measure: Change in Depressive Symptoms Index-Suicidality Subscale (DSI-SS) Score
timeFrame: Baseline to 30 days
measure: Change in Suicide Visual Analog Scale (S-VAS) Score
timeFrame: Baseline to 30 days
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: University Hospital
state: Texas
Study officials:
affiliation: UT Health San Antonio
name: Robert De Lorenzo, MD, MSM
role: PRINCIPAL_INVESTIGATOR
affiliation: UT Health San Antonio
name: Romeo Fairley, MD, MPH
role: STUDY_DIRECTOR
affiliation: UT Health San Antonio
name: Alan Peterson, PhD, ABPP
role: STUDY_DIRECTOR
affiliation: UT Health San Antonio
name: Stacey Young-McCaughan, RN, PhD
role: STUDY_DIRECTOR
References: